January 2007:

Ongoing expansion of Actelion’s infrastructure with opening of new clinical development facilities in Allschwil/Basel 

January 2007:

Actelion completes acquistion of US-based CoTherix Inc.

January 2007:

Publication in Nature Medicine of pre-clinical and early clinical findings with Actelion’s orexin receptor antagonist, almorexant

February 2007:

Successful proof-of-concept for Actelion’s orexin receptor antagonist, almorexant, in patients suffering from primary insomnia

March 2007:

Positive study results for Tracleer® in chronic thromboembolic pulmonary hypertension

June 2007:

1:5 stock split taking effect

June 2007:

Actelion receives EU marketing approval for Tracleer® for the reduction of the number of new digital ulcers in patients with systemic sclerosis and ongoing digital ulcer disease

September 2007:

Data presentations on orexin receptor antagonist, almorexant, at World Sleep Congress in Cairns, Australia, focusing on the therapeutic potential to restore normal physiological sleep in patients with primary insomnia

September 2007:

Initiation of proof-of-concept study with miglustat in cystic fibrosis

November 2007:

Initiation of Phase III clinical study (CONSCIOUS-2) with clazosentan to demonstrate prevention of vasospasm-related morbidity and mortality in subarachnoid hemorrhage

December 2007:

Actelion/Merck & Co., Inc. Renin alliance achieves fourth milestone; Phase II program initiated

December 2007:

Actelion celebrates 10 year anniversary; foundation stone is laid for its new Business Center

December 2007:

Actelion becomes full member of Interpharma, the Swiss Association of Pharmaceutical Research Companies

December 2007:

Initiation of Phase III study with endothelin receptor antagonist Actelion-1 to demonstrate safety and efficacy in delaying disease progression and mortality in patients with pulmonary arterial hypertension (PAH)

December 2007:

Actelion initiates Phase III program RESTORA with almorexant to confirm efficacy and safety in patients suffering from primary insomnia